New treatment modalities with vaccine therapy in renal cell carcinoma

Vaccination of Urological Cancer Patients With WT1 Peptide-Pulsed Dendritic Cells in Combination With Molecular Targeted Therapy or Conventional Chemotherapy Induces Immunological and Clinical Responses

Current status of clinical trials assessing oncolytic virus therapy for urological cancers

Immunomonitoring reveals interruption of anergy after vaccination in a case of type-2-papillary renal cell carcinoma

Recent advances in immuno-oncology and its application to urological cancers

Human renal carcinoma cells respond to Newcastle disease virus infection through activation of the p38 MAPK/NF-κB/IκBα pathway

Matched-pair analysis of dendritic cell versus targeted-therapy in patients with metastatic renal cell carcinoma

Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with high-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic response

Improved vaccine efficacy of tumor exosome compared to tumor lysate loaded dendritic cells in mice

A phase I, open label, dose escalation and cohort expansion study to evaluate the safety and immune response to autologous dendritic cells (DC) transduced with AdGMCA9 (DC-AdGMCAIX) in patients with mRCC.